To check efficacy of ripasudil in management of primary open angle glaucoma
- Conditions
- Health Condition 1: 4- Measurement and MonitoringHealth Condition 2: H401- Open-angle glaucoma
- Registration Number
- CTRI/2021/05/033754
- Lead Sponsor
- Dr Sowparnika A B
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Newly detected POAG / OHT.
2. POAG will be defined as:
a. IOP > 21 mmHg on atleast 2 occasions, atleast 24 has apart.
b. Optic nerve head showing CDR > 0.61 with significant thinning of the neuroretinal rim: or a CDR asymmetry of 0.2 > between 2 eyes.
c. Open angles on gonioscopy.
d. Automated visual field testing showing changes corresponding with the optic disc changes.
3. OHT will be defined as:
• IOP > 21 mmHg on atleast 2 occasions, 24 hrs apart.
• Open angles on gonioscopy
• Normal optic disc and visual field tests
4. Patients willing to participate in the study given a written informed consent and comply with the followup schedule.
1. Patients with POAG / OHT having IOP > 30 mmHg.
2. Patient with PACG and others secondary glaucoma.
3. Patient underwent surgery on the inner eye
4. Patient who changed glaucoma treatment after ripasudil administration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method measurement of IOPTimepoint: day 14, 1 month, 2months and 3 months
- Secondary Outcome Measures
Name Time Method safety and tolerability of Ripasudil in comparison with TimololTimepoint: day 14, 1 month, 2 months and 3 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.